SABER™ Bupivacaine, a novel extended-release formulation of bupivacaine for postoperative pain control...
- 15 October 2014
SABER™- Bupivacaine, a novel extended-release formulation of bupivacaine for postoperative pain control demonstrates dose-response, safety and no impact on surgical wound healing following inguinal herniorrhaphy.
SABER-Bupivacaine is an extended release formulation of bupivacaine in a resorbable matrix which provides delivery of bupivacaine at the site of administration over a period of 3 days. The formulation consists of three components: common local anesthetic bupivacaine (12%), organic matrix sucrose acetate isobutyrate, and a diluent, benzyl alcohol. Clinical benefits and safety of continuous infusions of bupivacaine into the surgical wound via elastomeric pumps was demonstrated following a variety of surgical procedures (Liu, 2006), including inguinal hernia repair (Lau, 2003; Sanchez, 2004). SABER-Bupivacaine formulation, a translucent thick solution, is designed to provide continuous delivery of bupivacaine once placed in the surgical wound at the same rate of 10-20 mg/h as delivered by elastomeric pumps through indwelling catheters. Multiple trials are ongoing to investigate safety and efficacy of SABER-Bupivacaine in various surgical procedures.
Hadj A, Nicholson D, Moodie J, Turner R, Watts R, Abrouk N, Langecker P, Lissin D.
Poster presentation American Society of Anaesthesiologists, October 15 2014.